| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel Becker, Olga Liver, Roberto Mester, Micha Rapoport, Abraham Weizman, Mordechai Weis. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. The Journal of clinical psychiatry. vol 64. issue 7. 2003-09-23. PMID:12934975. |
risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. |
2003-09-23 |
2023-08-12 |
Not clear |
| Daniel Becker, Olga Liver, Roberto Mester, Micha Rapoport, Abraham Weizman, Mordechai Weis. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. The Journal of clinical psychiatry. vol 64. issue 7. 2003-09-23. PMID:12934975. |
therefore, we compared hormone profiles and bone properties in female premenopausal schizophrenia patients treated with either risperidone or olanzapine. |
2003-09-23 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. |
2003-09-16 |
2023-08-12 |
Not clear |
| Stephen R Marder, Shirley M Glynn, William C Wirshing, Donna A Wirshing, Doreen Ross, Clifford Widmark, Jim Mintz, Robert P Liberman, Karen E Blai. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. The American journal of psychiatry. vol 160. issue 8. 2003-09-05. PMID:12900301. |
maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. |
2003-09-05 |
2023-08-12 |
Not clear |
| Stephen R Marder, Shirley M Glynn, William C Wirshing, Donna A Wirshing, Doreen Ross, Clifford Widmark, Jim Mintz, Robert P Liberman, Karen E Blai. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. The American journal of psychiatry. vol 160. issue 8. 2003-09-05. PMID:12900301. |
the authors compared symptom outcomes, side effects, and social adjustment in stable schizophrenia outpatients who received 2 years of maintenance treatment with risperidone or haloperidol. |
2003-09-05 |
2023-08-12 |
Not clear |
| D Gothelf, A Apter, J Reidman, A Brand-Gothelf, Y Bloch, G Gal, L Kikinzon, S Tyano, R Weizman, G Ratzon. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). vol 110. issue 5. 2003-08-08. PMID:12721815. |
olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. |
2003-08-08 |
2023-08-12 |
Not clear |
| D Gothelf, A Apter, J Reidman, A Brand-Gothelf, Y Bloch, G Gal, L Kikinzon, S Tyano, R Weizman, G Ratzon. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). vol 110. issue 5. 2003-08-08. PMID:12721815. |
to evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol. |
2003-08-08 |
2023-08-12 |
Not clear |
| Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang, Gui Ying Wu, Yu Cun She. The effect of risperidone treatment on superoxide dismutase in schizophrenia. Journal of clinical psychopharmacology. vol 23. issue 2. 2003-08-01. PMID:12640213. |
the effect of risperidone treatment on superoxide dismutase in schizophrenia. |
2003-08-01 |
2023-08-12 |
human |
| Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang, Gui Ying Wu, Yu Cun She. The effect of risperidone treatment on superoxide dismutase in schizophrenia. Journal of clinical psychopharmacology. vol 23. issue 2. 2003-08-01. PMID:12640213. |
forty-one inpatients with diagnosed schizophrenia (dsm-iii-r) were assigned to 12 weeks of treatment with risperidone at a fixed dosage of 6 mg/d after a 2-week washout period. |
2003-08-01 |
2023-08-12 |
human |
| Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang, Gui Ying Wu, Yu Cun She. The effect of risperidone treatment on superoxide dismutase in schizophrenia. Journal of clinical psychopharmacology. vol 23. issue 2. 2003-08-01. PMID:12640213. |
risperidone treatment significantly decreased the initially high blood sod levels in schizophrenia. |
2003-08-01 |
2023-08-12 |
human |
| R H Hunter, C B Joy, E Kennedy, S M Gilbody, F Son. Risperidone versus typical antipsychotic medication for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2003-07-28. PMID:12804396. |
risperidone versus typical antipsychotic medication for schizophrenia. |
2003-07-28 |
2023-08-12 |
Not clear |
| John M Kane, Mariëlle Eerdekens, Jean-Pierre Lindenmayer, Samuel J Keith, Michael Lesem, Keith Karche. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. The American journal of psychiatry. vol 160. issue 6. 2003-07-23. PMID:12777271. |
the authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. |
2003-07-23 |
2023-08-12 |
Not clear |
| Veena Kumari, Elizabeth Zachariah, Adrian Galea, Hugh C Jones, Mrigen Das, Ravi Mehrotra, David Taylor, Tonmoy Sharm. Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study. Journal of psychopharmacology (Oxford, England). vol 17. issue 1. 2003-07-22. PMID:12680744. |
this study determined the effects of procyclidine, an anticholinergic drug, on ppi in patients with schizophrenia given risperidone or quetiapine and not on any anticholinergic drugs, employing a placebo-controlled, cross-over design. |
2003-07-22 |
2023-08-12 |
human |
| Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, Jun Nakamur. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598823. |
plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. |
2003-07-15 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, Jun Nakamur. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598823. |
we have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons. |
2003-07-15 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, Jun Nakamur. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598823. |
in the present study, we focused on the clinical efficacy and mechanisms of risperidone towards positive symptoms in the acute phase of schizophrenia. |
2003-07-15 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, Jun Nakamur. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598823. |
thirty-four patients meeting dsm-iv criteria for schizophrenia and treated with risperidone alone were evaluated regarding their clinical improvement using the positive and negative syndrome scale (panss) before and 2 weeks after risperidone administration, and blood samples were also drawn at the same times. |
2003-07-15 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Nobuhisa Ueda, Koji Shinkai, Jun Nakamur. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598823. |
these results suggest that higher levels of plasma hva before risperidone administration might be a predictor of a good response to risperidone treatment, and the influence of risperidone on dopaminergic activity might be associated with its efficacy in treating symptoms of schizophrenia in the acute phase. |
2003-07-15 |
2023-08-12 |
Not clear |
| Gil Zalsman, Amos Frisch, Shaul Lev-Ran, Andrés Martin, Elena Michaelovsky, Daniela Bensason, Doron Gothelf, Eitan Nahshoni, Samuel Tyano, Abraham Weizma. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 13. issue 3. 2003-07-11. PMID:12729944. |
drd4 exon iii polymorphism and response to risperidone in israeli adolescents with schizophrenia: a pilot pharmacogenetic study. |
2003-07-11 |
2023-08-12 |
Not clear |
| Gil Zalsman, Amos Frisch, Shaul Lev-Ran, Andrés Martin, Elena Michaelovsky, Daniela Bensason, Doron Gothelf, Eitan Nahshoni, Samuel Tyano, Abraham Weizma. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 13. issue 3. 2003-07-11. PMID:12729944. |
this study examined the possible association between the polymorphism in the dopamine receptor drd4 gene and response to risperidone among 24 israeli jewish adolescent inpatients with first-episode schizophrenia. |
2003-07-11 |
2023-08-12 |
Not clear |